Tokyo Tape
Sign in
← Kaken Pharmaceutical

Quarterly report · Q2

4521.TEDINET S100S89K
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥36.2bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥73.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥36.8bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥5.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥8.2bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥5.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥8.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥5.7bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥8.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.4bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥171.7bnat 2023-09-30Cons.Assets
Total assets¥166.3bnat 2023-03-31Cons.Assets
Total assets¥167.3bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥30.9bnat 2023-09-30Cons.Liabilities
Total liabilities¥29.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥140.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥136.8bnat 2023-03-31Cons.Net assets
Net assets / equity¥140.4bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥55.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥59.6bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥70.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.3bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥75.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥245m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥9.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥7.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥4.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥108.182023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥41.292023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.82022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥158.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥81.452022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio82.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio81.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio83.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2023-04-01 → 2023-09-30¥661m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥7.6bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2022-04-01 → 2022-09-30¥616m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥8.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Dividends income noiPrior1YTDDuration233000000JPY
Dividends income noiCurrentYTDDuration251000000JPY
Subsidy income noiPrior1YTDDuration76000000JPY
Subsidy income noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration45000000JPY
Other noiCurrentYTDDuration22000000JPY
Non operating incomePrior1YTDDuration358000000JPY
Non operating incomeCurrentYTDDuration277000000JPY
Interest expenses noePrior1YTDDuration8000000JPY
Interest expenses noeCurrentYTDDuration8000000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration54000000JPY
Other noePrior1YTDDuration3000000JPY
Other noeCurrentYTDDuration5000000JPY
Non operating expensesPrior1YTDDuration12000000JPY
Non operating expensesCurrentYTDDuration67000000JPY
Ordinary incomePrior1YTDDuration8555000000JPY
Ordinary incomeCurrentYTDDuration5722000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration2000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration0JPY
Gain on sales of investment securities eiPrior1YTDDuration1000000JPY
Gain on sales of investment securities eiCurrentYTDDuration4000000JPY
Extraordinary incomePrior1YTDDuration4000000JPY
Extraordinary incomeCurrentYTDDuration5000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration25000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration69000000JPY
Impairment loss elPrior1YTDDuration304000000JPY
Impairment loss elCurrentYTDDuration－JPY
Other elPrior1YTDDuration－JPY
Other elCurrentYTDDuration0JPY
Extraordinary lossPrior1YTDDuration330000000JPY
Extraordinary lossCurrentYTDDuration69000000JPY
Income before income taxesPrior1YTDDuration8229000000JPY
Income before income taxesCurrentYTDDuration5658000000JPY
Income taxesPrior1YTDDuration2265000000JPY
Income taxesCurrentYTDDuration1590000000JPY
Profit lossPrior1YTDDuration5964000000JPY
Profit lossCurrentYTDDuration4068000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration－JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration－JPY
Profit loss attributable to owners of parentPrior1YTDDuration5964000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration4068000000JPY
Profit lossPrior1YTDDuration5964000000JPY
Profit lossCurrentYTDDuration4068000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration213000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration1748000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration31000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-2000000JPY
Other comprehensive incomePrior1YTDDuration245000000JPY
Other comprehensive incomeCurrentYTDDuration1745000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass